{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Vinflunine', 'Dose, Mode of Administration and Dose Modification:', 'Vinflunine will be administered intravenously on Day 1 of every 21-day cycle. The starting dose of', 'vinflunine 320 mg/m\u00b2 will be administered over a 20-minute period (or per local requirement)', 'unless otherwise specified below. In case of WHO/ECOG PS of > 1 or ECOG PS of 0 and prior', 'pelvic irradiation, vinflunine treatment should be started at the dose of 280 mg/m\u00b2. In the absence', 'of any hematological toxicity during the first cycle causing treatment delay or dose reduction, the', 'dose may be increased to 320 mg/m\u00b2 every 21-days for the subsequent cycles.', 'In subjects with moderate renal impairment (40 mL/min VI CrCI VI 60 mL/min), the recommended', 'dose is 280 mg/m\u00b2 given once every 21-day cycle. In subjects with renal impairment', '(30 mL/min VI CrCl < 40 mL/min), the recommended dose is 250 mg/m\u00b2 given once every 21-day', 'cycle. The recommended dose of vinflunine is 250 mg/m\u00b2 given once every 21-day cycle in', 'subjects with mild liver impairment (Child-Pugh grade A).', 'The doses recommended in subjects > 75 years old are as follows:', 'in subjects at least 75 years old but less than 80 years, the dose of vinflunine to be given is', '280 mg/m\u00b2 every 21-day cycle.', 'in subjects 80 years old and beyond, the dose of vinflunine to be given is 250 mg/m\u00b2 every', '21-day cycle.', 'Refer to local product label or SmPC and institution guidelines for vinflunine for further guidance', 'on vinflunine dosing.', 'Dose interruptions may last up to 6 weeks (2 cycles). Dose interruptions for subjects who are', \"deriving clinical benefit from treatment may be extended beyond 6 weeks, if the subject's toxicity\", 'does not otherwise require permanent discontinuation. Please refer to the approved product label', 'for specific dose modifications for subjects receiving vinflunine.', 'Paclitaxel', 'Dose, Mode of Administration and Dose Modification:', 'Study treatment of paclitaxel should be administered intravenously on Day 1 of every 21-day cycle', 'after all procedures/assessments have been completed. The starting dose of paclitaxel 175 mg/m\u00b2', 'will be administered as an intravenous infusion administered over 3 hours or per local requirement', 'See guidelines on adjustment of initial dose. Refer to local product label or SmPC and institution', 'guidelines for paclitaxel for further guidance on paclitaxel dosing.', 'All subjects should be premedicated prior to paclitaxel administration per institutional guidelines in', 'order to prevent severe hypersensitivity reactions. Such premedication may consist of', 'dexamethasone 20 mg orally administered approximately 12 and 6 hours before paclitaxel,', 'diphenhydramine (or its equivalent) 50 mg IV 30 to 60 minutes prior to paclitaxel, and cimetidine', '(300 mg) or ranitidine (50 mg) IV 30 to 60 minutes before paclitaxel. The appropriate', 'premedication regimen may be determined by the investigator.', 'Paclitaxel should not be administered to subjects with baseline neutrophil counts of less', 'than 1500 cells/mm\u00b3 Subjects should not be re-treated with subsequent cycles of', 'paclitaxel until neutrophils recover to a level > 1500 cells/mm\u00b3 and platelets recover to a', 'level > 100000/mm\u00b3 Severe conduction abnormalities have been documented in < 1% of', 'subjects during paclitaxel therapy and in some cases requiring pacemaker placement. If', 'subjects develop significant conduction abnormalities during paclitaxel infusion,', 'appropriate therapy should be administered and continuous cardiac monitoring should be', 'performed during subsequent therapy with paclitaxel.', '14 Sep 2020', 'Astellas', 'Page 26 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'In case of mild hepatic impairment (total bilirubin > 1.25 ULN), paclitaxel should be started at a', 'dose of 135 mg/m\u00b2.', 'Recommended dose modification guidelines specific for subjects receiving paclitaxel are detailed', 'in Table D below. Dose modifications should also be considered according to local product label or', 'SmPC and institutional guidelines.', 'Dose interruptions may last up to 6 weeks (2 cycles). Dose interruptions for subjects who are', \"deriving clinical benefit from treatment may be extended beyond 6 weeks, if the subject's toxicity\", 'does not otherwise require permanent discontinuation.', 'Table D', 'Recommended dose modifications for subjects receiving paclitaxel', 'Toxicity', 'Grade', 'Occurrence', 'Hold', 'Dose', 'Treatment', 'Treatment', 'Modification', 'Discontinuation', 'Peripheral', 'Grade 1, 2', 'No', '135 mg/m\u00b2', 'N/A', 'Neuropathy', 'Grade 3, 4', 'Yes', 'N/A', 'Discontinue upon', 'onset', 'Neutropenic', '1', 'Hold until', '135 mg/m\u00b2', 'fever (defined as', 'ANC', 'T> 100.5\u00b0F', '> 1,500/L', '(38.1\u00b0C) and', '2', 'Hold until', '100 mg/m\u00b2', 'ANC VI 1,000/L)', 'ANC', '> 1,500/L', '3', 'yes', 'N/A', 'Yes', 'N/A: not applicable; T: temperature', 'Discontinuation Criteria:', 'A discontinuation from treatment applies to a subject who enrolled in the study and for whom', 'study treatment is permanently discontinued for any reason.', 'The subject is free to withdraw from the study treatment and/or study for any reason and at any', 'time without giving reason for doing so and without penalty or prejudice. The investigator is also', \"free to discontinue the subject from study treatment or to terminate a subject's involvement in the\", \"study at any time if the subject's clinical condition warrants it. If a subject is discontinued from the\", 'study with an ongoing adverse event (AE) or an unresolved laboratory result that is significantly', 'outside of the reference range, the investigator will attempt to provide follow-up until the condition', 'stabilizes or no longer is clinically significant.', 'The following are discontinuation criteria from treatment for individual subjects:', 'Subject develops radiological disease progression.', 'Subject is required to receive another systemic anti-cancer treatment for underlying or new', 'cancer.', 'Subject develops unacceptable toxicity.', 'Female subject becomes pregnant.', \"Investigator decides it is in the subject's best interest to discontinue.\", 'Subject declines further treatment.', 'Subject is noncompliant with the protocol based on the investigator or medical monitor', 'assessment.', '14 Sep 2020', 'Astellas', 'Page 27 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}